..Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary… Continue reading Tolerability and Immunogenicity After a Late Second #Dose or a Third Dose of ChAdOx1 #nCoV-19 (AZD1222)
Category: Infectivology
Review of the Emerging Evidence Demonstrating the Efficacy of #Ivermectin in the Prophylaxis and Treatment of #COVID-19
This is a provisional file, not the final typeset article Article.pdfDownload
Predictive factors of #smell recovery in a clinical series of 288 #COVID-19 patients with olfactory dysfunction
To evaluate potential predictive factors of smell recovery in a clinical series of 288 patients presenting olfactory dysfunction (OD) related to the COVID19. Potential correlations are sought between epidemiological, clinical and immunological characteristics of patients and the persistence of OD at 60 days. MethodsCOVID-19 positive patients presenting olfactory dysfunction were prospectively recruited from three European… Continue reading Predictive factors of #smell recovery in a clinical series of 288 #COVID-19 patients with olfactory dysfunction
Common #dandelion (Taraxacum officinale) efficiently blocks the interaction between ACE2 cell surface receptor and #SARS-CoV-2 spike protein D614, mutants D614G, N501Y, K417N and E484K in vitro
bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive. On 11th March 2020, coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, was declared as a global pandemic by the World Health Organization (WHO). To date, there… Continue reading Common #dandelion (Taraxacum officinale) efficiently blocks the interaction between ACE2 cell surface receptor and #SARS-CoV-2 spike protein D614, mutants D614G, N501Y, K417N and E484K in vitro
Acute and long-term disruption of #glycometabolic control after #SARS-CoV-2 infection
Patients with coronavirus disease 2019 (COVID-19) are reported to have a greater prevalence of hyperglycaemia. Cytokine release as a consequence of severe acute respiratory syndrome coronavirus 2 infection may precipitate the onset of metabolic alterations by affecting glucose homeostasis. Here we describe abnormalities in glycometabolic control, insulin resistance and beta cell function in patients with… Continue reading Acute and long-term disruption of #glycometabolic control after #SARS-CoV-2 infection
Informed consent disclosure to vaccine trial subjects of risk of #COVID-19 vaccines worsening clinical disease
Aims of the study: Patient comprehension is a critical part of meeting medical ethics standards of informed consent in study designs. The aim of the study was to determine if sufficient literature exists to require clinicians to disclose the specific risk that COVID-19 vaccines could worsen disease upon exposure to challenge or circulating virus. Methods… Continue reading Informed consent disclosure to vaccine trial subjects of risk of #COVID-19 vaccines worsening clinical disease
Vaccine Breakthrough Infections with #SARS-CoV-2 Variants
Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks previously, we identified 2 women with vaccine breakthrough infection. Despite evidence of vaccine efficacy in both women, symptoms… Continue reading Vaccine Breakthrough Infections with #SARS-CoV-2 Variants
#Ivermectin for Prevention and Treatment of #COVID-19 InfectionA Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials. Areas of uncertainty:We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection. Data… Continue reading #Ivermectin for Prevention and Treatment of #COVID-19 InfectionA Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
Dynamic innate immune response determines susceptibility to #SARS-CoV-2 infection and early replication kinetics
Initial replication of SARS-CoV-2 in the upper respiratory tract is required to establish infection, and the replication levelcorrelates with the likelihood of viral transmission. Here, we examined the role of host innate immune defenses in restrictingearly SARS-CoV-2 infection using transcriptomics and biomarker-based tracking in serial patient nasopharyngeal samples andexperiments with airway epithelial organoids. SARS-CoV-2 initially… Continue reading Dynamic innate immune response determines susceptibility to #SARS-CoV-2 infection and early replication kinetics
2 Medical News 